1. Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease
Tamara N. Pereira, Peter J. Lewindon, Jeffery L. Smith, Therese L. Murphy, Douglas J. Lincoln, Ross W. Shepherd, Grant A. Ramm 
Journal of Hepatology 
Volume 41, Issue 4, Pages (October 2004)
DOI: /j.jhep
Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
(A) Serum TIMP-1 levels in patients with CFLD, CFnoLD and in control subjects. Serum TIMP-1 was significantly higher in CFLD patients compared to both CFnoLD patients and control subjects (ANOVA P<0.001). (B) Linear regression analysis of the correlation between serum TIMP-1 levels and the histological stage of hepatic fibrosis in patients with CFLD (r=−0.34, P=0.06).
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

3. Fig. 2
(A) Serum PH levels in patients with CFLD, CFnoLD and in control subjects. Serum PH was significantly higher in CFLD patients compared to both CFnoLD patients and control subjects (ANOVA P=0.008). (B) Linear regression analysis of the correlation between serum PH levels and the histological stage of hepatic fibrosis in patients with CFLD (r=−0.48, P=0.008).
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

4. Fig. 3
Serum CL-IV levels in patients with CFLD and CFnoLD and in control subjects. Serum CL-IV was significantly higher in CFLD patients compared to CFnoLD patients and control subjects (ANOVA P<0.001).
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

5. Fig. 4
Serum HA levels in patients with CFLD, CFnoLD and in control subjects. Serum HA was significantly higher in CFLD patients compared to control subjects (P=0.05), but not when compared to patients with CFnoLD.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

6. Fig. 5
ROC curves for serum concentrations of CL-IV, TIMP-1 and PH, individually and in combination, for discriminating CFLD patients from those CF patients without liver disease and Controls. The AUC are (P<0.0001), (P<0.0001), (P=0.0011) and (P<0.0001) for CL-IV, TIMP-1, PH and all three combined, respectively.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

7. Fig. 6
(A) ROC curve for the serum concentration of PH in discriminating patients with early fibrosis (stages 0 and 1) from those with extensive fibrosis (stages 2–4). The area under the curve is (P<0.0001). (B). ROC curve combining serum PH and TIMP-1 with logistic regression, for identifying CFLD patients with no fibrosis (stage 0) vs. those with any fibrosis (stages 1–4). The ROC AUC is (P<0.02).
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2004 European Association for the Study of the Liver Terms and Conditions